Phytopharm initiates Cogane Phase II trial
The Phase II study is expected to investigate the efficacy, safety and tolerability of Cogane administered for 28 weeks to approximately 400 patients with early stage Parkinson’s disease.
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.